| Faculty Member | Research Summary |
| Andrey Anokhin, Ph.D. | 1) genetics of human brain functioning in relation to addiction; |
| Laura Jean Bierut, M.D. | 1) genetic studies of psychiatric illnesses; 2) genetic studies of substance dependence; |
| Kevin J. Black, M.D. | 1) neuroimaging; 2) Tourette Syndrome; 3) neuropsychiatry of movement disorders; 4) clinical neuropsychiatry; |
| Kelly N. Botteron, M.D. | 1) Magnetic Resonance Imaging (MRI) studies of child and adolescent affective and attentional disorders; 2) MRI studies of normal brain development; 3) imaging studies in twin populations; 4) genetics of brain structure and structural correlates of neuropsychiatric disorder; 5) development/implementation of image analysis methods for neuromorphometric analysis of MRI; |
| Kathleen Keenan Bucholz, Ph.D. | 1) development and course of alcohol use, abuse and dependence in general population, family and twin samples; 2) effects of alcohol dependence on health services use and costs; 3) psychiatric assessment and classification; |
| Robert M. Carney, PH.D. | 1) the significance of psychiatric and psychosocial factors in patients with heart disease; 2) cognitive-behavioral treatment of anxiety and affective disorders; 3) psychiatric comorbidity in medical patients; |
| Theodore J. Cicero, PH.D. | 1) gender differences in the actions and abuse liability of substances of abuse, particularly morphine and cocaine; 2) basic investigations of the role of endogenous opioid peptides in neuroendocrinology; |
| C. Robert Cloninger, M.D. | 1) genetic epidemiology of neuropsychiatric disorders; 2) nosology of psychiatric disorders; 3) neurogenetic adaptive processes in personality and psychopathology; |
| John N. Constantino, M.D. | 1) the influence of genetic and environmental influences on early social development; 2) prevention of antisocial behavior and violence; 3) longitudinal research on the life course and genetic structure of autistic social impairment; 4) in depth study of the intergenerational transmissions of attachment; 5) development of a manulized curriculum for promoting parent-infant attachment; 6) analysis of the association between monoamine neurotransmitters and child behavior; 7) publication of a quantitative measure of autistic traits, the Social Responsiveness Scale ; 8) early intervention program for the prevention of child maltreatment; |
| Gabriel de Erausquin, M.D., PH.D. | 1) mechanism of dopaminergic neuronal death in Parkinson's disease and in transplants of embryonic mesencephalon; 2) selective susceptibility of specific dopaminergic neuronal projections to excitotoxicity during development and its role in the development of schizophrenic pathology; 3) imaging of neurotransmitter receptors in schizophrenia; |
| Nuri B. Farber, M.D. | 1) pharmacological, neuroanatomical, histochemical, and cognitive/behavioral evaluation of neurodegeneration; 2) glutamate, GABA receptors; 3) psychotic disorders; 4) Alzheimer's disease; 5) developmental disorders; |
| Kenneth E. Freedland, Ph.D. | 1) psychiatric comorbidity in coronary heart disease and congestive heart failure; 2) cognitive-behavioral treatment of depression and anxiety; 3) role and treatment of mental stress in coronary disease; |
| Anne L. Glowinski, M.D., MPE. | 1) genetic epidemiology of adolescent depression; 2) genetic epidemiology of youth suicidal behavior; 3) parental alcoholism; 4) gene-environment interplay in early childhood psychopathology; |
| Alison M. Goate, D.PHIL. | 1) Positional cloning of dementia loci; 2) Association studies in late onset alzheimer's disease; 3) Molecular genetics of nicotine dependence; 4) Molecular genetics of alzheimer's disease (AD) and other dementias; 5) Molecular genetics of alcholism; |
| Dan W. Haupt, MD | 1) Metabolic effects of valproate augmentation of antipsychotic treatment; 2) Metabolic effects of antipsychotics in children; 3) Metabolic effects of antipsychotics in schizophrenia patients; 4) Psychopharmacology of schizophrenia; 5) Psychopharmacology of bipolar disorder; |
| Andrew C. Heath, D.PHIL. | 1) alcoholism etiology and consequences; 2) genetic studies of alcoholism, smoking, and drug dependence; 3) genetic studies of depression, suicidality and anxiety disorders; 4) genetic studies of personality and personality disorder; 5) methodological research in genetic epidemiology; |
| Tamara Hershey, Ph.D. | 1) neural underpinnings of cognitive dysfunction in diseases relevant to dopamine and the basal ganglia; 2) effects of metabolic insults such as hypoglycemia on the brain and cognitive function; |
| Barry A. Hong, Ph.D., FAACP | 1) psychological and psychiatric aspects of chronic illness in particular renal failure, liver disease; 2) behavior effecting organ donation; 3) disaster research and training; 4) follow-up studies of living donors; |
| Keith E. Isenberg, MD | 1) molecular biology of ligand gated ion channels, neural nicotinic acetylcholine receptor, 5HT3 receptor, GABA a receptor and glutamate receptor; 2) administration of electroconvulsive therapy (ECT); |
| Yukitoshi Izumi, MD, Ph.D. | 1) LTP: memory mechanisms related with development, aging and neuronal disorders such as hypoglycemia and anoxia; 2) experimental neuropathology with brain slices and retinal preparations; relationship between excitotoxicity and energy deficiency; |
| Michael R. Jarvis, MD, Ph.D. | 1) maintenance electroconvulsive therapy; 2) psychopharmacology; 3) emergency and inpatient psychiatry; 4) psychiatric education; |
| Eric Lenze | 1) NIMH R01, Pharmacotherapy of late life Generalized Anxiety Disorder; 2) R01, Risk genes for late life depression after hip fracture; 3) pilot work: CBT augmentation of SSRI in late life Generalized Anxiety Disorder; 4) pilot work: aripiprazole augmentation of antidepressants for treatment-resistant depression; 5) pilot work: enhanced medical rehabilitation (PT and OT) for late-life depression; |
| Collins E. Lewis, MD | 1) alcoholism and comorbid disorders; 2) Vietnam veterans with PTSD; |
| Joan L. Luby, MD | 1) preschool mood disorders; 2) infant/preschool psychopathology and nosology; 3) social/emotional development of the infant and toddler; 4) treatment of childhood affective disorders; |
| Patrick J. Lustman, Ph.D. | 1) examination of the interaction of mental and physical illness, including studies of the prevalence, course, and treatment of psychiatric illness in patients with diabetes mellitus and/or gastrointestinal disorders; |
| Pamela A.F. Madden, Ph.D. | 1) genetic studies on nicotine use and dependence; 2) the relationship between genetic influences on smoking behavior, and genetic factors responsible for the use and dependence on other substances (using alcohol as a model system); 3) genetic studies of possible mediators of genetic influence on cigarette use and the development of dependence on nicotine and other substances; |
| Daniel Mamah, M.D., M.P.E. | 1) High Dimensional Brain Mapping of Subcortical and Cortical Structures; 2) Diffusion Tensor Imaging (DTI) of White Matter Fiber Tracts; 3) Basic Pathophysiologic Mechanisms in Schizophrenia spectrum disorders; 4) Psychiatric Epidemiology; |
| Steven Mennerick, Ph.D. | 1) physiology of glutamate and GABA signaling; 2) axonal physiology; 3) synaptic homeostasis and plasticity; |
| Krista Moulder, Ph.D. | 1) synaptic plasticity and effects of neuronal activity; 2) mechanisms and modulation of neurotransmitter release; 3) neuronal survival; |
| Elliot C. Nelson, M.D. | 1) twin study of social phobia; 2) genetic epidemiology of childhood abuse; 3) case-control candidate gene study of opioid dependence; |
| Rosalind Joyce Neuman, Ph.D. | 1) statistical and mathematical methods to localize genes underlying susceptibility to psychiatric illnesses; 2) using clustering methods to refine clinically heterogeneous phenotypes (in particular alcohol dependence) to more homogeneous forms; |
| John W. Newcomer, M.D. | 1) Metabolic and cardiovascular risk factors in individuals with neuropsychiatric disorders; 2) Metabolic effects of antipsychotics in children; 3) Regulation of memory performance in humans; 4) Therapies for neuropsychiatric disorders, particularly psychotic disorders; |
| Bruce Nock, Ph.D. | 1) opiate abuse and stress; 2) morphine-stress-glucocorticoid interactions; 3) opiate use and susceptibility to posttraumatic stress disorder; |
| Petra Nowotny, Ph.D. | 1) genotyping SNPs to find susceptibility genes for late-onset Alzheimer's disease; 2) functional effects of associated SNPs; 3) allele-specific gene expression of associated SNPs; |
| John W. Olney, M.D. | 1) role of excitatory transmitter dysfunction and associated neuronal degeneration (both excitotoxic and apoptotic) in both neurodevelopmental and adult-onset psychiatric disorders; |
| Michele Pergadia, Ph.D. | 1) Genetic and environmental influences on nicotine withdrawal; 2) Genetic and environmental influences on personality; |
| Rumi Kato Price, Ph.D., MPE | 1) long-term effects of early truama, psychopathology, substance abuse, and trauma; 2) coping and protective factors mitigating suicidal risk; 3) virtual trauma exposure method to identify PTSD vulnerability factors; 4) human-genome epidemiology for substance use disorders and psychiatric comorbidity; 5) application of flexible computational techniques to epidemiologic data; |
| Thomas R. Przybeck, Ph.D. | 1) structure and measurement of personality; 2) validation of the seven factor model of temperament and character; 3) cross-cultural research on personality and personality disorders; 4) instrument development; |
| Wendy Reich, Ph.D. | 1) Children of psychiatrically ill parents, especially parents with alcoholism, ASP, and bipolar disorder; 2) instrument development for the assessment of psychopathology in children four to eighteen, as well as the assessment of their home and social environment; 3) cross-cultural assessment; 4) behavior disorders in children; 5) development of training programs to teach use of child instruments; |
| Angela M. Reiersen, M.D. | 1) Autistic Traits and Motor Problems in Children with ADHD: I have been working on a project investigating autistic traits and motor problems in a population-based twin sample enriched for ADHD.; |
| John Rice, Ph.D. | 1) method development in genetic epidemiology; 2) quantitative genetics; 3) genetics of affective disorders; 4) linkage analysis; 5) diagnostic stability/validity; 6) analysis of multivariate data, especially survival and logistic analyses; 7) analysis of whole genome association data; |
| Stephen L. Ristvedt, Ph.D. | 1) symptom appraisal in physical disease, particularly psychological impediments and cues to seeking diagnosis for signs or symptoms; 2) personality and dispositional influences on health-related behaviors; |
| John W. Rohrbaugh, Ph.D. | 1) brain electrical and psychophysiological studies of attention and cognition in normal subjects and in psychiatric patients; |
| Eugene H. Rubin, M.D., Ph.D. | 1) Depression and co-morbid medical illnesses; 2) Dementia; 3) Trends in psychiatric education; 4) Issues involving financial conflicts of interest at academic health centers; |
| Jeffrey F. Scherrer, Ph.D. | 1) behavior genetic approaches in psychiatric epidemiology; 2) environmental influences on young adult liability to abuse licit and illicit substances; 3) comorbidity; 4) veterans health; 5) physical outcomes in depression and PTSD; 6) pathological gambling; 7) incident heart disease in VA patients with depression; |
| Yvette I. Sheline, MD | 1) structural brain changes associated with major depression; 2) PET and fMRI studies of brain function in major depression, particularly in relation to treatment response; |
| Erik J. Sirevaag, Ph.D. | 1) alcohol and substance use and related disorders; |
| Catherine Woodstock Striley Ph.D., MSW, LCSW, ACSW, MPE | 1) racial/ethnic and gender disparities in health care (including mental health and substance abuse treatment); 2) barriers to mental health care and substance abuse treatment; 3) refugee and immigrant mental health; 4) psychiatric nosology and epidemiology; 5) research ethics; |
| Brian K. Suarez, Ph.D. | 1) genetic epidemiology of psychiatric disorders where a major gene is implicated; 2) linkage studies of Mendelian diseases with emphasis on theoretical issues involved in mapping recessives in endogamous populations; |
| Richard D. Todd, PhD, MD | 1) Genetic linkage, association and brain imaging studies of familial forms of psychiatric disorders,; 2) Mutation screening and genome wide association studies of attention deficit/hyperactivity disorder (ADHD) and nicotine/alcohol dependence; 3) Gene X environment studies of children at high familial risk for psychiatric disorders such as depression and ADHD; 4) Genetic studies of normal behaviors; |
| Dorothy Van Buren, Ph.D. | 1) lifestyle interventions for youth with Type 2 diabetes and their families; 2) psychological treatments for binge eating disorder; 3) family based, behavioral treatments for pediatric obesity; 4) behavioral family therapy with adolescents with anorexia nervosa; |
| Richard D. Wetzel, Ph.D. | 1) clinical and epidemiological studies of suicide; 2) clinical studies of cognitive functioning in psychiatric disorders; 3) research on cognitive therapy; 4) clinical neuropsychology; 5) validation of the TCI; 6) dissociative phenomena; 7) multiple personality; |
| Denise E. Wilfley, Ph.D. | 1) causes, characterization, and treatment of obesity and eating disorders; 2) assessment and psychological treatments for eating disorders and obesity; 3) prevention of eating disorders and obesity in at-risk populations; 4) maintenance treatments for childhood obesity; 5) behavioral lifestyle intervention for obese children and their parents; 6) family-based and pharmacological interventions applied to the treatment of anorexia nervosa; |
| David F. Wozniak, Ph.D. | 1) the role of excitatory amino acids in aging and development, Alzheimer;s disease, schizophrenia and other neuropsychiatric disorders; 2) the involvement of glutamate receptors in learning and memory, and neuronal injury and degeneration; 3) rodent models of developmental neuropsychiatric syndromes such as the fetal alcohol syndrome resulting from neonatal exposure to drugs of abuse and anesthetic agents; 4) behavioral phenotyping of mutant mice and the development of mouse models of human diseases; |
| Charles F. Zorumski, MD | 1) mechanisms regulating the actions of glutamate and GABA in the hippocampus; 2) short- and long-term synaptic plasticity in the hippocampus; 3) mechanisms involved in CNS neurodegeneration; |
